<DOC>
	<DOCNO>NCT00526396</DOCNO>
	<brief_summary>The purpose study compare activity fix dose cisplatin etoposide toxicity adjust dose drug first-line treatment small cell lung cancer .</brief_summary>
	<brief_title>STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study</brief_title>
	<detailed_description>The standard treatment advance small cell lung cancer ( SCLC ) combination chemotherapy cisplatin carboplatin etoposide . Standard fix dos combination base calculate patient 's body surface area . This method dose calculation show poorly correlate activity many chemotherapy drug , patient obtain adequate level drug circulation . Recent report suggest patient high tolerability chemotherapy ( without significant toxicity ) , risk less effectiveness therapy . This study compare fix dos standard chemotherapy new strategy chemotherapy dos adjust accord toxicity observe .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Cytologic histologic diagnosis small cell lung cancer Extensive disease accord VALG classification One target lesion . Performance status ( ECOG ) 0 1 Age &lt; 70 year . Patients asymptomatic cerebral metastasis eligible Patients complete treatment radiation therapy least 4 week prior enrollment eligible Written inform consent Previous chemotherapy Previous concomitant malignant neoplasm ( exclude adequately treat baso spinocellular skin carcinoma carcinoma situ cervix ) Neutrophil &lt; 2000/mm3 , platelet &lt; 100,000/mm3 , haemoglobin &lt; 10 g/dl Creatinine &gt; 1.5 x upper normal limit GOT and/or GPT &gt; 2.5 and/or Bilirubin &gt; 1.5 time upper normal limit absence hepatic metastasis GOT and/or GPT &gt; 5 and/or Bilirubin &gt; 3 time upper normal limit presence hepatic metastasis Any concomitant pathology would , investigator 's opinion , contraindicate use drug study Hypersensitivity darbepoetin alpha , rHuEPO component Uncontrolled hypertension . Inability provide inform consent . Inability comply followup</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>chemotherapy</keyword>
	<keyword>toxicity adjust dose</keyword>
</DOC>